SeaSpine Holdings Receives a Buy from H.C. Wainwright

In a report released today, Swayampakula Ramakanth from H.C. Wainwright reiterated a Buy rating on SeaSpine Holdings (NASDAQ: SPNE), with a price target of $15. The company’s shares closed yesterday at $10.83.

According to TipRanks.com, Ramakanth is a 3-star analyst with an average return of 4.0% and a 34.9% success rate. Ramakanth covers the Healthcare sector, focusing on stocks such as Diffusion Pharmaceuticals Inc, IntelGenx Technologies, and Eleven Biotherapeutics.

SeaSpine Holdings has an analyst consensus of Moderate Buy, with a price target consensus of $16.

Find more picks by Best Performing Analysts >>

Based on SeaSpine Holdings’ latest earnings report for the quarter ending December 31, the company posted quarterly revenue of $33.98 million and GAAP net loss of $7.51 million. In comparison, last year the company earned revenue of $31.89 million and had a GAAP net loss of $9.1 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

SeaSpine Holdings Corp. is a medical technology company, which focuses on design, development and commercialization of surgical solutions for the treatment of patients suffering from spinal disorders. The company has a comprehensive portfolio of orthobiologics and spinal fusion hardware solutions to meet the varying combinations of products that neurosurgeons and orthopedic spine surgeons need to perform fusion procedures on the lumbar, thoracic and cervical spine. SeaSpine Holdings was founded on February 12, 2015 and is headquartered in Carlsbad, CA.